StockNews.com Begins Coverage on Cutera (NASDAQ:CUTR)

Analysts at StockNews.com initiated coverage on shares of Cutera (NASDAQ:CUTR) in a research report issued on Friday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Stock Down 4.3 %

Shares of CUTR opened at $0.35 on Friday. The company has a market cap of $7.07 million, a P/E ratio of -0.05 and a beta of 1.26. Cutera has a fifty-two week low of $0.28 and a fifty-two week high of $4.97. The firm’s 50 day moving average price is $0.48 and its 200 day moving average price is $0.93.

Institutional Investors Weigh In On Cutera

Several large investors have recently bought and sold shares of CUTR. Bank of Montreal Can boosted its stake in shares of Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after buying an additional 35,248 shares during the period. Squarepoint Ops LLC raised its holdings in Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 70,870 shares in the last quarter. Finally, Ground Swell Capital LLC acquired a new stake in Cutera in the second quarter valued at approximately $37,000. Hedge funds and other institutional investors own 90.70% of the company’s stock.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.